BRAF and melanoma: A pooled analysis including KEYNOTE-001, KEYNOTE-002, and KEYNOTE-006 study endorses the use of pembrolizumab for treatment of advanced melanoma independent of BRAF V600 mutation status or previous treatment with BRAF inhibitor with or without MEK inhibitor.